69 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
post-operative period. Patients will have access to IV hydromorphone, a Schedule II opioid, for rescue of breakthrough pain. Avenue aims to initiate
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … to opioid stacking on IV tramadol relative to an approved opioid analgesic. We announced in April 2023 that the Company received official meeting
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic … of respiratory depression related to opioid stacking on IV tramadol relative to an approved opioid analgesic. We announced in April 2023 that the Company received
8-K
EX-99.1
zx06gfnfqjgvrd
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B3
kdps0m6cgk
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-99.1
aiz2wokjr70b1 6qpq
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B4
pnkmw7fl75ocmjm9
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
goqr309omksya
5 Oct 23
Free writing prospectus
5:05pm
FWP
9syhz0ib nk6x6r25
3 Oct 23
Free writing prospectus
5:47pm
8-K
EX-99.1
mmo89xt
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
424B3
un3qtscb8cgi9z a519z
28 Jun 23
Prospectus supplement
4:56pm